logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASH 2019 – R/R B-cell NHL: mosunetuzumab shows promise in phase 1/1b trial

Mosunetuzumab could augment the effect of prior CAR-T treatment.